Form 4: Celldex Therapeutics Executive Sarah Cavanaugh Reports Stock Transactions

Sarah Cavanaugh, SVP of Corporate Affairs & Administration at Celldex Therapeutics, reported the exercise of stock options and sale of common stock on May 30, 2024.

Summary

• On May 30, 2024, Sarah Cavanaugh, SVP of Corporate Affairs & Administration at Celldex Therapeutics, exercised stock options to acquire 10,750 shares at $2.78 and 10,103 shares at $9.0165.
• She also sold 20,853 shares of common stock at a weighted average price of $33.7282, with prices ranging from $33.465 to $34.06 per share.
• Following these transactions, Cavanaugh directly owns 1,860 shares of common stock and 22,713 shares of common stock.
• She also owns 0 incentive stock options at $2.78 and 0 incentive stock options at $9.0165.

Sentiment

Score: 5

Explanation: This is a neutral disclosure of stock transactions. It doesn't inherently indicate positive or negative sentiment about the company's prospects.

Industry Context

This Form 4 filing is a routine disclosure of insider transactions, providing transparency to the market regarding the buying and selling activities of company executives. It's a standard practice for publicly traded companies.

Comparison to Industry Standards

• Form 4 filings are a standard requirement for publicly traded companies in the US, ensuring transparency in insider trading activities.
• Similar filings are made by executives at comparable biotech companies like Amgen, Biogen, and Gilead Sciences, providing insights into their stock ownership and trading patterns.
• The reported transactions are typical for executives who receive stock options as part of their compensation packages.

Stakeholder Impact

• The transactions may have a minor impact on shareholders as they provide insight into executive's perspective on the company's stock value.
• Employees who participate in the Employee Stock Purchase Plan may be interested in these transactions.

Key Dates